Billiontoone, Inc. (NASDAQ:BLLN) Receives Average Rating of “Moderate Buy” from Brokerages

Billiontoone, Inc. (NASDAQ:BLLN) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $125.2857.

Several research firms have commented on BLLN. Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wells Fargo & Company decreased their price target on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, BTIG Research decreased their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th.

Insider Activity

In other Billiontoone news, insider Nancy Joann Johnson sold 10,582 shares of Billiontoone stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $100.47, for a total transaction of $1,063,173.54. Following the transaction, the insider directly owned 21,900 shares of the company’s stock, valued at approximately $2,200,293. This trade represents a 32.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Oguzhan Atay sold 26,250 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $97.66, for a total transaction of $2,563,575.00. Following the completion of the transaction, the insider owned 20,000 shares in the company, valued at $1,953,200. This represents a 56.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 83,582 shares of company stock valued at $8,312,361.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BLLN. Green Alpha Advisors LLC bought a new position in shares of Billiontoone in the fourth quarter worth approximately $436,000. FNY Investment Advisers LLC bought a new position in shares of Billiontoone in the fourth quarter worth approximately $497,000. Massachusetts Financial Services Co. MA bought a new position in shares of Billiontoone in the fourth quarter worth approximately $13,373,000. Baillie Gifford & Co. bought a new position in shares of Billiontoone in the fourth quarter worth approximately $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Billiontoone in the fourth quarter worth approximately $1,348,000.

Billiontoone Trading Up 4.2%

Shares of BLLN opened at $112.24 on Friday. The firm’s 50 day simple moving average is $91.82 and its 200 day simple moving average is $87.11. The company has a market capitalization of $5.16 billion and a P/E ratio of 204.07. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. Billiontoone has a 1-year low of $61.96 and a 1-year high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. The company’s revenue for the quarter was up 83.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.39) earnings per share. Sell-side analysts forecast that Billiontoone will post 0.93 earnings per share for the current fiscal year.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.